Publications by authors named "H-J Arends"
Background And Objectives: To investigate CSF findings in relation to clinical and electrodiagnostic subtypes, severity, and outcome of Guillain-Barré syndrome (GBS) based on 1,500 patients in the International GBS Outcome Study.
Methods: Albuminocytologic dissociation (ACD) was defined as an increased protein level (>0.45 g/L) in the absence of elevated white cell count (<50 cells/μL).
Background And Objectives: Infections play a key role in the development of Guillain-Barré syndrome (GBS) and have been associated with specific clinical features and disease severity. The clinical variation of GBS across geographical regions has been suggested to be related to differences in the distribution of preceding infections, but this has not been studied on a large scale.
Methods: We analyzed the first 1,000 patients included in the International GBS Outcome Study with available biosamples (n = 768) for the presence of a recent infection with , hepatitis E virus, , cytomegalovirus, and Epstein-Barr virus.
Article Synopsis
- AZD7442 (Evusheld) is a treatment for COVID-19 that uses two monoclonal antibodies, tixagevimab and cilgavimab, administered either intramuscularly (i.m.) or intravenously (i.v.).
- A study compared the pharmacokinetics (PKs) of a 600 mg i.m. dose in the thigh to a 300 mg i.v. dose in patients with symptomatic COVID-19, finding similar serum concentrations after 3 days from both routes.
- The results indicated that i.m. administration provides almost equivalent exposure to the i.v. method, suggesting it could enhance treatment access and maintain consistent antibody levels.
Article Synopsis
- Some cancer cells can become resistant to certain drugs called MEK inhibitors by making more of proteins like BRAF or KRAS, which helps them keep growing.
- When doctors stop giving the MEK inhibitors, the cells with extra BRAF can go back to being sensitive to the drug again, but this doesn't happen with cells that have KRAS.
- This means that for cells with BRAF problems, taking breaks from the medicine might help, but for KRAS, stopping the drug won't work and might even make the situation worse.
CFB (complement factor B) is elevated in adipose tissue and serum from patients with type 2 diabetes mellitus and cardiovascular disease, but the causal relationship to disease pathogenesis is unclear. Cfb is also elevated in adipose tissue and serum of the spontaneously hypertensive rat, a well-characterized model of metabolic syndrome. To establish the role of CFB in metabolic syndrome, we knocked out the gene in the spontaneously hypertensive rat.
View Article and Find Full Text PDF